ENTRY       D05386                      Drug
NAME        Pegaptanib sodium (JAN/USAN);
            Macugen (TN)
FORMULA     C294H342F13N107O188P28(C2H4O)n. 28Na
REMARK      ATC code: S01LA03
EFFICACY    Aging-related macular degeneration therapeutic agent, Angiogenesis inhibitor, Anti-VEGF aptamer
  TYPE      RNA aptamer
COMMENT     Pegaptanib inhibits VEGF165 selectively.
            Treatment of age-related macular degeneration disease
TARGET      VEGFA [HSA:7422] [KO:K05448]
  PATHWAY   hsa04370(7422)  VEGF signaling pathway
            hsa05200(7422)  Pathways in cancer
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             S SENSORY ORGANS
              S01 OPHTHALMOLOGICALS
               S01L OCULAR VASCULAR DISORDER AGENTS
                S01LA Antineovascularisation agents
                 S01LA03 Pegaptanib
                  D05386  Pegaptanib sodium (JAN/USAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Growth factors (RTK-binding)
                VEGFA
                 D05386  Pegaptanib sodium (JAN/USAN)
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D05386
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05386
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D05386
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D05386
DBLINKS     CAS: 222716-86-1
            PubChem: 47207062
            NIKKAJI: J2.229.653A
///
